Table 1 Comparison of clinical and pathological characteristics
Characteristic | All n = 1280 | Young (age ≤ 45) n = 150 | Non-young (age>45) n = 1130 | p |
|---|---|---|---|---|
Age | 56.27 ± 9.00 | 39.93 ± 0.39 | 58.44 ± 0.21 | < 0.001 |
Pathological type | ||||
endometrioid | 1183(92.4%) | 142(94.7%) | 1041(92.1%) | 0.26 |
Non endometrioid | 97(7.6%) | 8(5.3%) | 89(7.9%) | |
2009FIGO staging | < 0.01 | |||
Ia | 592(46.3%) | 86(57.3%) | 506(44.8%) | 0.004 |
Ib | 525(41.0%) | 34(22.7%) | 491(43.5%) | < 0.001 |
II | 163(12.7%) | 30(20.0%) | 133(11.8%) | 0.004 |
Risk classification | < 0.01 | |||
Low risk | 359(28.0%) | 58(38.7%) | 301(26.7%) | 0.002 |
Intermediate risk | 354(27.7%) | 21(14.0%) | 333(29.5%) | < 0.001 |
High-intermediate risk | 240(18.8%) | 27(18.0%) | 213(18.8%) | 0.802 |
High risk | 324(25.3%) | 44(29.3%) | 280(24.8%) | 0.228 |
Differentiation | ||||
G1: Well differentiated | 419(32.7%) | 63(42.0%) | 356(31.5%) | 0.98 |
G2: Moderately differentiated | 537(42.0%) | 49(32.7%) | 488(43.2%) | |
G3/4: Poorly/Undifferentiated | 233(18.2%) | 31(20.7%) | 202(17.9%) | |
Gx: Undetermined | 91(7.1%) | 7(4.7%) | 84(7.4%) | |
Deep Myometrial infiltration (≥ 1/2 or < 1/2) | ||||
≥ 1/2 | 608(47.5%) | 46(30.7%) | 562(49.7%) | < 0.001 |
Unknown | 8(0.6%) | 2(1.3%) | 6(0.6%) | |
Lymphovascular space invasion (+/-) | ||||
(+) | 227(17.7%) | 26(17.3%) | 201(17.8%) | 0.891 |
Lower uterine segment invasion (+/-) | ||||
(+) | 349(27.3%) | 70(46.7%) | 279(24.7%) | < 0.001 |
Unknown | 1(0.08%) | 0 | 1(0.09%) | |
Cervical invasion | ||||
(-) | 1024(80.0%) | 105(70.0%) | 919(81.3%) | 0.006 |
Interstitial infiltration | 163(12.7%) | 30(20.0%) | 133(11.8%) | |
Gland infiltration | 92(7.2%) | 14(9.3%) | 78(6.9%) | |
Unknown | 1(0.08%) | 1(0.7%) | 0 | |
Maximum diameter of tumor | 3.40 ± 1.89 | 4.18 ± 2.22 | 3.27 ± 1.81 | < 0.001 |
Unknown | 455(35.5%) | 43(28.7%) | 412(36.5%) | |
Surgery type (comprehensive or partial) | ||||
Comprehensive surgical staging | 887(69.2%) | 115(76.7%) | 772(68.3%) | 0.071 |
Unknown | 38(3.0%) | 2(1.3%) | 36(3.2%) | |
Adjuvant therapy (chemoradiotherapy/radiotherapy) | ||||
Chemoradiotherapy | 253(19.8%) | 35(23.3%) | 218(19.3%) | 0.49 |
Unknown | 83(6.5%) | 10(6.7%) | 73(6.5%) | |
Radiotherapy modality | ||||
VBT | 627(48.9%) | 77(51.3%) | 550(48.7%) | 0.77 |
EBRT | 155(12.1%) | 16(10.7%) | 139(12.3%) | |
VBT + EBRT | 498(38.9%) | 57(38.0%) | 441(39.0%) | |
With second primary tumor | 42(3.3%) | 4(2.7%) | 38(3.4%) | 0.81 |
Acute side effects | 660(51.6%) | 68(45.3%) | 592(52.4%) | 0.104 |
Lower gastrointestinal | 496(38.8%) | 50(33.3%) | 446(39.5%) | 0.154 |
Upper gastrointestinal | 282(22.0%) | 35(23.3%) | 247(21.9%) | 0.898 |
Urinary system | 137(10.7%) | 13(8.7%) | 124(11.0%) | 0.320 |
Hematologic system | 295(23.0%) | 34(22.7%) | 261(23.1%) | 0.801 |
Late side effects | 318(28.2%) | 29(22.1%) | 289(29%) | 0.100 |
Gastrointestinal | 153(13.6%) | 10(7.7%) | 143(14.4%) | 0.056 |
Urinary system | 72(6.4%) | 3(2.3%) | 69(6.9%) | 0.239 |
Hematologic system | 61(5.4%) | 9(6.9%) | 52(5.2%) | 0.431 |
Lower limb edema | 98(8.7%) | 7(5.4%) | 91(9.1%) | 0.455 |